Yellowstone: Mining HLA class II for TCR therapies

Yellowstone is using a platform built around HLA class II-presented antigens to address the target discovery bottleneck in immuno-oncology, identifying cancer-selective targets from a largely untapped antigen source and designing T cell receptor-based therapies against them.

Yellowstone Bioscience Ltd. launched in 2024 with $22 million from Syncona Ltd. (LSE:SYNC) to turn two decades of acute myelogenous leukemia (AML) patient biobank research from Paresh Vyas and colleagues at the University of Oxford into T cell receptor (TCR) bispecifics...